The live biotherapeutic elicited a 2.3% drop in weight loss in patients, which was maintained for weeks after dosing had ...

Women who suffer greater menopause symptoms are more likely to experience memory and thinking problems as they age, research ...

A study published in the Proceedings of the National Academy of Sciences has unveiled that brain aging follows a distinct yet ...

Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...

Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in ...

Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development!

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

OPGx-MERTK is a gene therapy being developed by Opus Genetics to treat patients impacted by MERTK-related retinitis pigmentosa (RP). Results from a pre-clinical study which evaluated OPGx-MERTK in a ...

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...

Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of ...

Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...